GT Biopharma (GTBP) Research & Development (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Research & Development of $413000.0 for Q1 2026, down 62.42% year-over-year from $1.1 million in Q1 2025, and down 69.99% quarter-over-quarter from $1.4 million in Q4 2025.
GT Biopharma (GTBP) Research & Development (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Research & Development for 14 consecutive years, with $413000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 62.42% year-over-year to $413000.0; the TTM figure through Mar 2026 stood at $2.8 million (down 54.48% YoY), while the FY2025 annual figure was $3.5 million, down 40.12% from the prior year.
- Research & Development retreated to $413000.0 in Q1 2026 per GTBP's latest filing, from $1.4 million in the prior quarter.
- Across five years, Research & Development topped out at $2.8 million in Q4 2022 and bottomed at $363000.0 in Q2 2025.
- Historically, Research & Development has averaged $1.5 million across 5 years, with a median of $1.4 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development surged 172.12% — and 2025, when it sank 79.65%.
- GT Biopharma's Research & Development stood at $2.8 million in 2022, then slumped by 52.25% to $1.4 million in 2023, then soared by 42.23% to $1.9 million in 2024, then slipped by 28.7% to $1.4 million in 2025, then sank by 69.99% to $413000.0 in 2026.
- Business Quant data shows GTBP's Research & Development at $413000.0 in Q1 2026, $1.4 million in Q4 2025, and $634000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 413,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 413,000.00 |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | 634,000.00 |
| Jun 30, 2025 | 363,000.00 |
| Mar 31, 2025 | 1.10 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | 777,000.00 |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 2.84 Mn |
| Sep 30, 2022 | 2.74 Mn |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 2.09 Mn |
| Dec 31, 2021 | 6.30 Mn |
| Sep 30, 2021 | 1.01 Mn |
| Jun 30, 2021 | 639,000.00 |